Thailand at a glance
- Population
- 71.6 million 2025
- Life expectancy at birth
- 76.6 years, 2024
- People aged 65 and over
- 16.0 % of people, 2025
- Health spending per person
- 327 US$ per person, 2023
- Doctors
- 0.54 per 1,000 people, 2021
Updated
Reviewed by Vidhi Upadhyay
Thailand MASH (NASH) Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Stage, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$66.6 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $2.0 Mn | — | — |
| 2025 (base) | $2.8 Mn | +$0.9 Mn | — |
| 2026 (forecast) | $4.1 Mn | +$1.2 Mn | +42.6% |
| 2027 (forecast) | $5.8 Mn | +$1.7 Mn | +103.3% |
| 2028 (forecast) | $8.3 Mn | +$2.5 Mn | +190% |
| 2029 (forecast) | $11.8 Mn | +$3.5 Mn | +313.5% |
| 2030 (forecast) | $16.8 Mn | +$5.0 Mn | +489.7% |
| 2031 (forecast) | $23.9 Mn | +$7.2 Mn | +740.8% |
| 2032 (forecast) | $34.1 Mn | +$10.2 Mn | +1,099% |
| 2033 (forecast) | $48.7 Mn | +$14.5 Mn | +1,609.8% |
| 2034 (forecast) | $69.4 Mn | +$20.7 Mn | +2,338.2% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $2.8 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $69.4 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 42.6% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Also called | MASH Drugs |
| Segments | Drug class, stage and end user (see all) |
| Key players | Madrigal Pharmaceuticals, Novo Nordisk A/S, Akero Therapeutics, 89bio, Inventiva and 1 more (see all) |
| Regulator in Thailand | Thai FDASource: Thai Food and Drug Administration. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
MASH therapeutics treat metabolic dysfunction-associated steatohepatitis, a serious fatty liver disease that can lead to cirrhosis and liver failure.
Key segments of the MASH (NASH) Therapeutics market include drug class (THR-beta Agonists, GLP-1 Agonists and FGF21 Analogs) and stage (Fibrosis Stage F2-F3 and Compensated Cirrhosis).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the MASH (NASH) Therapeutics market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the MASH (NASH) Therapeutics market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the MASH (NASH) Therapeutics market. Long-term safety data and lifestyle support are still needed for many patients.
The MASH (NASH) Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines need registration with the Thai Food and Drug Administration (Thai FDA).[1] The Universal Coverage Scheme, run by the National Health Security Office (NHSO), covers people outside the social security and civil servant schemes.[2]
[1] Thai Food and Drug Administration. Checked 14 Nov 2026.
[2] National Health Security Office. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for MASH (NASH) Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Thailand.
What doctors and scientists are doing in MASH (NASH) Therapeutics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.
From our blog
Thailand · 1 shared keyword
Thailand · 1 shared keyword
Thailand
Thailand
Thailand
Thailand
Medical Devices · Thailand
Medical Devices · Thailand
Medical Devices · Thailand
Medical Devices · Thailand
Healthcare Services · Thailand
Medical Devices · Thailand